Floatz logo

Cytarabine

T-Cell Acute Lymphoblastic Leukemia

SWOG Cancer Research NetworkSmall moleculePhase 3Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
73/ 100

Competitive context

75 Active assets in the T-Cell Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Vincristine Sulfate
Children's Oncology Group
Phase 3BB
Pegaspargase
Children's Oncology Group
Phase 3BB
Mercaptopurine Anhydrous
SWOG Cancer Research Network
Phase 3BB
Crisantaspase
University of Washington
Phase 3BB
Daunomycin
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Cytarabine is also rated in:

acute promyelocytic leukemiaActive
A
Indicative · Phase 4
82 / 100
View asset →
adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative · Phase 3
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →